(Q43850205)

27 November 2017

1 reference

title

Current status of anti-HBV chemotherapy (English)

1 reference

27 November 2017

1 reference

J H Hong

1

1 reference

27 November 2017

Y Choi

2

1 reference

27 November 2017

B K Chun

3

1 reference

27 November 2017

K Lee

4

1 reference

27 November 2017

C K Chu

5

1 reference

27 November 2017

publication date

1 April 1998

1 reference

Archives of Pharmacal Research

27 November 2017

published in

1 reference

27 November 2017

volume

21

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

89-105

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02974012

27 November 2017

exact match

0 references

cites work

Phase I trial of 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU) terminated by severe neurologic toxicity.

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Carbohydrate-Specific Receptors of the Liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Treatment and prevention of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Multiple nuclear dots antinuclear antibodies are not specific for primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Therapy of chronic hepatitis B with a 6-month course of ribavirin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Trisodium Phosphonoformate, a New Antiviral Compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

A cell culture assay for compounds which inhibit hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

In vitro metabolism of 1-beta-D-arabinofuranosylcytosine and 1-beta-2'-fluoroarabino-5-iodocytosine in normal and herpes simplex type 1 virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Inhibition of hepatitis B virus production by modified 2',3'-dideoxy-thymidine and 2',3'-dideoxy-5-methylcytidine derivatives. In vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Compact organization of the hepatitis B virus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Molecular therapeutic strategies in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

The mechanism of inhibition of hepatitis B virus replication by the carbocyclic analog of 2′-deoxyguanosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Acyclovir, oral, intravenous and combined with interferon for chronic HBeAg-positive hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Tumour necrosis factor to treat chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissues of ducklings infected in ovo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-.beta.-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Nucleosides. 129. Synthesis of antiviral nucleosides: 5-alkenyl-1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)uracils

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Quantitative polymerase chain reaction for hepatitis B virus DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

Inhibitory effects of selected antiviral compounds on human hepatitis B virus DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

BMS-200475, a novel carbocyclic 2′-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

21 January 2018

The hepatitis B virus

1 reference

https://api.crossref.org/works/10.1007%2FBF02974012

21 January 2018

Identifiers

DOI

10.1007/BF02974012

1 reference

Dimensions Publication ID

27 November 2017

1038079406

0 references

1 reference